Compare SIM & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIM | TLX |
|---|---|---|
| Founded | 1969 | 2015 |
| Country | Mexico | Australia |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 2.2B |
| IPO Year | 2002 | N/A |
| Metric | SIM | TLX |
|---|---|---|
| Price | $30.80 | $7.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $21.13 |
| AVG Volume (30 Days) | 895.0 | ★ 311.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $32.88 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.60 | $6.28 |
| 52 Week High | $34.59 | $19.93 |
| Indicator | SIM | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 57.84 |
| Support Level | $26.61 | $7.72 |
| Resistance Level | $33.00 | $8.19 |
| Average True Range (ATR) | 0.61 | 0.23 |
| MACD | 0.11 | 0.13 |
| Stochastic Oscillator | 66.20 | 86.31 |
Grupo Simec SAB de CV is a diversified producer, processor and distributor of SBQ steel and structural steel products with production and commercial operations. The group's SBQ products are used across a range of engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment. Its structural steel products are used in the non-residential construction market and other construction applications. Its segments are Mexico, Brazil, and the United States. The maximum of its sales is from the Mexico segment.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.